Results: Melanoma

Results from Abstracts

Pick one of the followings

*Some genes may be words of complete meaning. In any case, if present, they are relevant key words.

Legend:

***	p-value <= 0.001
**	p-value <= 0.01
*	p-value <= 0.05
n.s.	not significant

Top Ranked Genes, Molecules or Short Names*

Braf ***
F10 ***
Hr **
Cdc25c *
Gzmb *
Magea6 *
Card16 *
Icos *
Itga11 *
Sp6 *
Golm1 *
Pmel *
Map2k2 *
Mc1r *
Gsdmd *
Mitf *
Ccl20 *
Sln *
Aim2 *
Pir *
Lag3 n.s.
Nodal n.s.
Wee1 n.s.
Bap1 n.s.
Cspg4 n.s.
Atf1 n.s.
Lat n.s.
Cxcl5 n.s.
Cd80 n.s.
Mcam n.s.
Ctla4 n.s.
Mnt n.s.
Sf3b1 n.s.
Nlrc4 n.s.
Cd27 n.s.
Nog n.s.
Mtap n.s.
Ran n.s.
Tbp n.s.
Aes n.s.
Cxcl9 n.s.
Pam n.s.
Gnaq n.s.
Mdm2 n.s.
Ifng n.s.
Chek2 n.s.
Rig n.s.
Klf4 n.s.
Asip n.s.
Cck n.s.
Zeb1 n.s.
Foxp3 n.s.
Tlr7 n.s.
Prame n.s.
Vegfa n.s.
Cxcl10 n.s.
Mmp2 n.s.
Mut n.s.
Isg15 n.s.
Stat3 n.s.
Cdk4 n.s.
Kit n.s.
Kdr n.s.
Mmp9 n.s.
Ago2 n.s.
Bax n.s.
Srsf2 n.s.
U2af1 n.s.
Mageb18 n.s.
Magea8 n.s.
Mageb6 n.s.
Magel2 n.s.
Mageh1 n.s.
Maged2 n.s.
Magec3 n.s.
Magef1 n.s.
Magea5 n.s.
Magee2 n.s.
Maged4 n.s.
Mageb4 n.s.
Ntrk1 n.s.
Aldh1a3 n.s.
Atf4 n.s.
Calm1 n.s.
Scaper n.s.
Spint1 n.s.
Ercc6 n.s.
Nos2 n.s.
Ercc8 n.s.
Ptch2 n.s.
Gli1 n.s.
Lrig2 n.s.
Pin1 n.s.
Foxd3 n.s.
Cmklr1 n.s.
Il1rn n.s.
Ocln n.s.
Aco1 n.s.
Drosha n.s.
Rps27 n.s.

Top Ranked Key Phrases

Sentinel lymph node biopsy slnb ***
Non small cell lung cancer ***
Sentinel lymph node biopsy ***
Immune related adverse events ***
Squamous cell carcinoma scc ***
Basal cell carcinoma bcc ***
Immune checkpoint inhibitors ici ***
Immune checkpoint inhibitors icis ***
Non melanoma skin cancer ***
Progression free survival pfs ***
Non melanoma skin cancers ***
Squamous cell carcinoma ***
Cell cycle arrest ***
Kaplan meier method ***
Basal cell carcinoma ***
Cd8 t cells ***
Lymph node metastasis ***
Renal cell carcinoma ***
Anti pd 1 antibody ***
Immune checkpoint inhibitors ***
Melanoma cell lines ***
Immune checkpoint blockade ***
Braf v600e mutation ***
Tumor bearing mice ***
Braf mek inhibitors ***
American joint committee ***
Anti pd 1 therapy ***
Progression free survival **
Dose dependent manner **
Immune checkpoint inhibition **
B16f10 melanoma cells **
Pd l1 expression **
Overall survival os **
Human melanoma cells **
Photodynamic therapy pdt **
Cutaneous malignant melanoma **
Uveal melanoma um **
Uveal melanoma cells **
Primary malignant melanoma **
Tumor microenvironment tme **
Malignant melanoma mm **
Present study was *
Metastatic melanoma patients *
Cell lines *
Lymph nodes *
Adverse events *
Cell cycle *
T vec *
T cells *
A375 cells *
Anti pd 1 *
Checkpoint inhibitors *
Mek inhibitors *
Immune cells *
Cell death n.s.
Pd l1 n.s.
B16f10 cells n.s.
Protein levels n.s.
Skin reactions n.s.
Nk cells n.s.
Braf inhibitors n.s.
Tumor tissue n.s.
Tumor cells n.s.
Immune response n.s.
Significantly higher n.s.
Cell proliferation n.s.
Durable responses n.s.
Cell viability n.s.
Primary tumor n.s.
Um cells n.s.
Tumor growth n.s.
Pd 1 blockade n.s.
High rates n.s.
Was associated n.s.
Sun protection n.s.
Single agent n.s.
Adverse effects n.s.
Multivariate analysis n.s.
Meta analysis n.s.
Anti ctla 4 n.s.
Human melanoma n.s.
Significantly associated n.s.
Median os n.s.
Skin cancer n.s.
Cancer cells n.s.
Overall survival n.s.
Gene expression n.s.
Tumor thickness n.s.
Gastric cancer n.s.
Normal cells n.s.
Sun exposure n.s.
Mitotic rate n.s.
Tumor microenvironment n.s.
High risk n.s.
Improved survival n.s.
High expression n.s.

Top Ranked Mesh Terms

Skin neoplasms ***
Melanoma ***
Immunotherapy **
Neoplasm staging *
Kaplan-meier estimate *
Pathology *
Proto-oncogene proteins c-kit *
Bcl-2-associated x protein *
Positron-emission tomography *
Nevus *
Mitogen-activated protein kinases *
Theranostic nanomedicine *
Carcinoma merkel cell *
Lymphocytes tumor-infiltrating *
Fluorodeoxyglucose f18 *
Radiopharmaceuticals *
Lymphatic metastasis *
Photosensitizing agents *
Photochemotherapy *
Registries *
Monophenol monooxygenase *
Cd8-positive t-lymphocytes *
Proportional hazards models *
Neoplasm recurrence local *
Rna small interfering *
Early detection of cancer *
Tumor microenvironment *
Aged 80 and over *
Esophageal neoplasms *
Telomerase *
Polyethylene glycols *
Autophagy *
United states *
Programmed cell death 1 receptor *
Uveal neoplasms *
Melanins *
Gene expression regulation neoplastic *
Micrornas *
Nf-kappa b n.s.
Databases factual n.s.
Follow-up studies n.s.
Aged n.s.
Incidence n.s.
Bone neoplasms n.s.
Antineoplastic combined chemotherapy protocols n.s.
Middle aged n.s.
Tumor cells cultured n.s.
Asian continental ancestry group n.s.
Colorectal neoplasms n.s.
Proto-oncogene proteins b-raf n.s.
Lymphocyte activation n.s.
Ultraviolet rays n.s.
Sentinel lymph node biopsy n.s.
Carcinoma basal cell n.s.
Sentinel lymph node n.s.
Real-time polymerase chain reaction n.s.
Lymph nodes n.s.
Survival analysis n.s.
Lymph node excision n.s.
Clinical trials as topic n.s.
Drug therapy n.s.
Drug delivery systems n.s.
Liver neoplasms n.s.
Antineoplastic agents n.s.
Macrophages n.s.
Radiation effects n.s.
Head and neck neoplasms n.s.
Positron emission tomography computed tomography n.s.
Retrospective studies n.s.
Disease-free survival n.s.
Cell survival n.s.
Antibodies monoclonal humanized n.s.
Risk assessment n.s.
Nanoparticles n.s.
Mortality n.s.
China n.s.
Up-regulation n.s.
Drug resistance neoplasm n.s.
Combined modality therapy n.s.
T-lymphocytes n.s.
Neoplasm metastasis n.s.
Molecular targeted therapy n.s.
Prognosis n.s.
Cell line tumor n.s.
Neoplasm invasiveness n.s.
Neoplasm proteins n.s.
Age factors n.s.
Melanoma experimental n.s.
Cohort studies n.s.
Ctla-4 antigen n.s.
Drug synergism n.s.
Cytochromes c n.s.
Biopsy n.s.
Aldehyde oxidoreductases n.s.
Apoptosis n.s.
Treatment outcome n.s.
Inflammasomes n.s.
Caspase 1 n.s.
Psoriasis n.s.
Dermatologic agents n.s.

Results for: Melanoma

Results from Abstracts

KEGG Pathways

Gene Ontology Biological Processes